Supplementary Figure 3 from Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 52KB, MEHD7945A is more potent than the combination of cetuximab and erlotinib
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361895597